Science Advances

Supplementary Materials

This PDF file includes:

  • Fig. S1. LVs markers and intrarenal interstitial inflammatory cells of the LVslow and LVshigh groups in kidneys of CKD patients.
  • Fig. S2. Renal fibrosis is accompanied by atrophy.
  • Fig. S3. Flow cytometry gating strategies.
  • Fig. S4. THP protein in RDLNs.
  • Fig. S5. Conditional KD of LVs elicited by DT injection in mice that did not undergo surgery.
  • Fig. S6. Conditional KD of LVs in LYVE-1-Cre/iDTR mice attenuated UUO-induced lymphocyte expansion in both RDLN and spleen, intrarenal inflammatory infiltration, and loss of capillaries.
  • Fig. S7. Conditional KD of LVs in LYVE-1-Cre/iDTR mice attenuated IRI-induced splenomegaly, perirenal lymphadenectasis, intrarenal inflammation, and fibrosis at day 14.
  • Fig. S8. sVEGFR3-FC or sLYVE-1-FC attenuated lymphatic endothelial proliferation but did not induce apoptosis in vitro.
  • Fig. S9. sVEGFR3-FC (sR3) or sLYVE-1-FC (sLY) attenuated intrarenal lymphatic endothelium proliferation, renal inflammation, and fibrosis.
  • Table S1. Patient clinical and demographic characteristics.

Download PDF

Files in this Data Supplement: